Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia.
We describe 3 cases of malignant pheochromocytoma with multiple metastases which were treated with cyclophosphamide, vincristine and dacarbazine (CVD) combination chemotherapy and alpha-methyl-p-tyrosine. Case 1 was operated on first but hypercatecholaminemia could not be completely controlled. Cases 2 and 3 received chemotherapy, CVD combination chemotherapy and/ or alpha-methyltyrosine and good control of hypercatecholaminemia was attained. In all cases it was possible to control hypercatecholaminemia during most of the time they were administered a-methyltyrosine despite the presence of tumors. None of the patients suffered hypertension crises. In our patients treatment with CVD plus a-methyl-p-tyrosine proved to be safe and ameliorated the clinical course.
Tada
K
K
Department of Endocrinology and Metabolism, Institute of Clinical Medicine, University of Tsukuba, Japan.
Okuda
Y
Y
Yamashita
K
K
D000310:Adrenal Gland Neoplasms / Q000188:drug therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002395:Catecholamines / Q000097:blood*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D010673:Pheochromocytoma / Q000188:drug therapy*; D013125:Spinal Neoplasms / Q000188:drug therapy / Q000556:secondary; D014750:Vincristine / Q000627:therapeutic use; D019805:alpha-Methyltyrosine / Q000627:therapeutic use*
D002395:Catecholamines; D014750:Vincristine; D019805:alpha-Methyltyrosine; D003606:Dacarbazine; D003520:Cyclophosphamide